The US Food and Drug Administration has approved Journavx, also known as suzetrigine 50 milligram oral tablets—a ...
Predicting who will transition from acute to chronic pain is the “holy grail” of pain neuroscience. A novel biomarker ...
Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...